AU2003301759A1 - Human vps4a and vps4b functions in viral budding - Google Patents

Human vps4a and vps4b functions in viral budding

Info

Publication number
AU2003301759A1
AU2003301759A1 AU2003301759A AU2003301759A AU2003301759A1 AU 2003301759 A1 AU2003301759 A1 AU 2003301759A1 AU 2003301759 A AU2003301759 A AU 2003301759A AU 2003301759 A AU2003301759 A AU 2003301759A AU 2003301759 A1 AU2003301759 A1 AU 2003301759A1
Authority
AU
Australia
Prior art keywords
vps4a
vps4b
human
functions
viral budding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003301759A
Other versions
AU2003301759A8 (en
Inventor
Jennifer E. Garrus
Wesley I. Sundquist
Uta K. Von Schwedler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Original Assignee
University of Utah Research Foundation UURF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF filed Critical University of Utah Research Foundation UURF
Publication of AU2003301759A8 publication Critical patent/AU2003301759A8/en
Publication of AU2003301759A1 publication Critical patent/AU2003301759A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2003301759A 2002-05-15 2003-05-15 Human vps4a and vps4b functions in viral budding Abandoned AU2003301759A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38102702P 2002-05-15 2002-05-15
US60/381,027 2002-05-15
US38270202P 2002-05-21 2002-05-21
US60/382,702 2002-05-21
US45114603P 2003-02-28 2003-02-28
US60/451,146 2003-02-28
PCT/US2003/015722 WO2004039311A2 (en) 2002-05-15 2003-05-15 Human vps4a and vps4b functions in viral budding

Publications (2)

Publication Number Publication Date
AU2003301759A8 AU2003301759A8 (en) 2004-05-25
AU2003301759A1 true AU2003301759A1 (en) 2004-05-25

Family

ID=32234152

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003301759A Abandoned AU2003301759A1 (en) 2002-05-15 2003-05-15 Human vps4a and vps4b functions in viral budding

Country Status (2)

Country Link
AU (1) AU2003301759A1 (en)
WO (1) WO2004039311A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003283990B2 (en) * 2002-10-01 2009-04-30 Eli Lilly And Company Anti-TSG101 antibodies and their uses for treatment of viral infections

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476009B2 (en) 2002-10-01 2013-07-02 Functional Genetics, Inc. Methods for detecting enveloped virus infections by measuring cell surface TSG101
CN105288655B (en) * 2015-05-29 2019-03-29 中国人民解放军第二军医大学 Application of the vacuole sorting protein 4A in preparation prevention and treatment enterovirns type 71 infection medicine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981602A (en) * 1992-06-30 1999-11-09 John B. Davidson Methods of using Ajoene for inhibiting integrin-mediated cell-cell fusion

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003283990B2 (en) * 2002-10-01 2009-04-30 Eli Lilly And Company Anti-TSG101 antibodies and their uses for treatment of viral infections

Also Published As

Publication number Publication date
AU2003301759A8 (en) 2004-05-25
WO2004039311A2 (en) 2004-05-13
WO2004039311A3 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
AU2003213835A1 (en) Multiple-property composite beads and preparation and use thereof
AU2003272187A1 (en) Novel nanoparticles and use thereof
AU2003228445A1 (en) Tissue composites and uses thereof
AU2002364051A1 (en) Anti-cancer combination and use thereof
AU2001264258A1 (en) Nonwoven-fabric laminate and use thereof
AUPS096302A0 (en) Improvements in and relating to food
WO2003099841A9 (en) Peptides and the use thereof in darkening the skin
AU2003296369A1 (en) Imminoamines and preparation thereof
AU2003207824A1 (en) K-type polarizer and preparation thereof
AU7458201A (en) Laminate and use thereof
AU2003212891A1 (en) K-type polarizer and preparation thereof
AU2003272423A1 (en) Centrosome proteins and uses thereof
AU2003267361A1 (en) Orthopoxvirus antigens and use thereof
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2003231827A1 (en) Pseudo-tissues and uses thereof
AU2003207628A1 (en) Structural and cytoskeleton-associated proteins
AU2003301759A1 (en) Human vps4a and vps4b functions in viral budding
AU2003209459A1 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
AU2003244437A1 (en) Quinoxalinones and their use especially in the treatment of cardiovascular diseases
AU2003280992A1 (en) Novel proteins and use thereof
AU2003292774A1 (en) Novel proteins and use thereof
AU2003228397A1 (en) HAUSP-p53 INTERACTION AND USES THEREOF
AUPS037002A0 (en) Viral variants and uses therefor
AU2003301356A1 (en) Modelling and design integration
AU2003258291A1 (en) HTLV-I p30II AND p12I PROTEINS AS THERAPEUTIC TARGETS IN HTVL-I INFECTED INDIVIDUALS

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase